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ABSTRACT
Transcripts of NANOG and OCT4 have been recently
identified in human t(4;11) leukemia and in a model
system expressing both t(4;11) fusion proteins.
Moreover, downstream target genes of NANOG/
OCT4/SOX2 were shown to be transcriptionally
activated. However, the NANOG1 gene belongs to
a gene family, including a gene tandem duplication
(named NANOG2 or NANOGP1) and several pseudo-
genes (NANOGP2-P11). Thus, it was unclear which
of the NANOG family members were transcribed
in t(4;11) leukemia cells. 50-RACE experiments
revealed novel 50-exons of NANOG1 and NANOG2,
which could give rise to the expression of two dif-
ferent NANOG1 and three different NANOG2 protein
variants. Moreover, a novel PCR-based method was
established that allows distinguishing between tran-
scripts deriving from NANOG1, NANOG2 and all
other NANOG pseudogenes (P2–P11). By applying
this method, we were able to demonstrate that
human hematopoietic stem cells and different
leukemic cells transcribe NANOG2. Furthermore,
we functionally tested NANOG1 and NANOG2
protein variants by recombinant expression in 293
cells. These studies revealed that NANOG1 and
NANOG2 protein variants are functionally equivalent
and activate a regulatory circuit that activates
specific stem cell genes. Therefore, we pose the
hypothesis that the transcriptional activation of
NANOG2 represents a ‘gain-of-stem cell function’
in acute leukemia.
INTRODUCTION
The NANOG protein—in combination with OCT4
and SOX2—was shown to be suﬃcient to establish an
embryonic stem cell program. Since the discovery of
NANOG in 2003 (1,2), NANOG has drawn very much
attention, and the ‘core NANOG network’ has been
unraveled for human and murine embyronic stem (ES)
cells by ChIP-on-Chip experiments (3,4). Stem cell
functions of the core NANOG network are maintained
by the help of the Polycomb repressor complex II
(PRC II: SUZ12, EED, EZH2) which speciﬁcally
silences genes coding for transcription factors necessary
for the development of all three germ layers and
neuronal development (5).
Tumor research has been widely improved by the
concept of cancer-initiating cells (6). Cancer-initiating
cells provide features of stem cells, however, diﬀerent
tumors seem to use diﬀerent pathways to obtain
stemness (7), and little is known about the molecular
mechanisms that are required to establish this unique
cell population.
Recently, we have discovered that NANOG transcrip-
tion was signiﬁcantly enhanced (16-fold) in murine
ﬁbroblast when stably transfected with expression
constructs coding for the MLL AF4 and AF4 MLL
fusion genes, deriving from the chromosomal transloca-
tion t(4;11)(q21;q23) (8). This genetic aberration is
associated with high-risk acute lymphoblastic leukemia
and very poor outcome. Subsequent analyses of the
core NANOG network provided ﬁrst evidence
that NANOG downstream targets were indeed transcrip-
tionally activated, while NANOG/PRCII-repressed
genes were transcriptionally silenced. To verify this
unusual ﬁnding, leukemic cells deriving from adult and
pediatric t(4;11) patients were investigated and revealed
the same transcriptional proﬁle (8). Thus, it seems that
the population of t(4;11) leukemia cells—or at least a
small fraction thereof—is able to turn on a stem cell
program similar to the core NANOG network identiﬁed
in ES cells.
A precise analysis of NANOG transcription, however, is
hampered by the fact that NANOG1 is transcribed along
with several retroposed pseudogenes of the NANOG
family, also demonstrating that NANOG2 (alias
NANOGP1) is a tandem duplication of NANOG1 (9).
The comparison of human and chimpanzee genome
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sequences, while NANOGP2 to P11 are dispersed,
intronless and reverse transcribed integrants (10).
Transcription of NANOG2 and NANOG pseudogenes
(NANOGP2, P4, P5, P7 and P8) has been demonstrated
for a large variety of diﬀerent solid tumors (11,12). Thus,
transcripts deriving from NANOG1, NANOG2 or these
pseudogene copies can only be distinguished by cloning
and sequencing the resulting PCR amplimers. Based on
their speciﬁc mutation spectrum (missense, frame shift or
deletion) their origin can be elucidated.
Therefore, we started a detailed investigation of the
NANOG gene family and their transcriptional properties,
using MLL-rearranged leukemic cells that seem to be
capable of re-activating a NANOG-dependent stem cell
program, probably as part of their pathological
properties.
MATERIAL AND METHODS
Cell culture
SEM, RS4;11, KOPN8 and NOMO1 cells were cultured
in RPMI 1640 containing 10% fetal calf serum.
NTERA-2, HEK-293 and HEK-293T cells were main-
tained in DMEM supplemented with 10% fetal calf
serum (and 5% horse serum for NTERA-2 cells). All
media were supplemented with 1% L-glutamine and 1%
Pen/Strep.
Total RNA extraction and reverse transcription
RNA was prepared from NTERA-2, SEM, RS4;11,
KOPN-8 and NOMO-1 cell lines using the Qiagen
RNeasy Mini Kit (Qiagen, Germany). The protocol was
slightly changed to extract only cytosolic RNA (in order
to prevent genomic DNA contamination for pseudogene
analysis). One microgram RNA was reverse transcribed
using hexamer primers in a total volume of 25ml. Final
cDNA synthesis was diluted to 50ml using sterile water. In
addition, all isolated RNAs were directly tested in PCR
reactions to exclude any contamination with genomic
DNA (data not shown). Five microliters of each cDNA
was used as template in 50ml PCR reactions throughout
all experiments.
NANOG-speciﬁc RT–PCR experiments
Initial RT–PCR experiments were carried out by using
three diﬀerent primer sets (a–c). Two of these pair sets
(a and b) speciﬁcally bind to transcripts deriving from
NANOG1, NANOG2 and all other NANOG pseudogenes
(P2–P11). Primer set c binds to the 50-ﬂanking UTR of
NANOG1 and NANOG2 (one mismatch) and to an
internal exon. Primer sets were as follows: set a
(50-gatcagatctAACATGAGTGTGGATCCAGCTTGT
C-30;5 0-ggaattcTCACACGTCTTCAGGTTGCATGT
TC-30) results in a 938-bp PCR amplimer; set b (50-GCC
TCCAGCAGATGCAAGAAC-30;5 0-GCAGGAGAATT
TGGCTGGAAC-30) produces a 418-bp PCR amplimer;
set c (50-ATTATAAATCTAGAGACTCC-30;5 0-TTGTT
TGCCTTTGGGACTGGT-30) results in a 444-bp PCR
amplimer. The NANOG2-speciﬁc primer set d (50-GTTA
ATGTGGTTACAAAAC GTGAC-30;5 0-GCCACCTCT
TAGATTTCATTCTCTGGTTCTGG-30) should pro
duce a 351-bp PCR amplimer. Finally, a NANOGP8-
speciﬁc primer set e (50-CAAAGCTTGCCTTGCTTTG
AAGA-30;5 0-CTGGTGGTAGGAAGAGTAAAGG-30)
resulted in a 525-bp amplimer. All ampliﬁcations were
carried out with a denaturation step at 94 C for 2min
followed by 35 cycles with the following proﬁle: 30s at
94 C, 30s at 58 C (45 C for set c; 59 C for set e) and
30s at 72 C; a ﬁnal extension step at 72 C for 5min was
performed for all reactions. QPCR experiments were per-
formed by using the NANOG1-speciﬁc oligonucleotides
50-CCTTCAGCAAAGAACAAAGCTTC-30 and 50-TGT
CTATCCCTCCTCCCAGGTAG-30 (hybridizing to
NANOG1 exon 1b and exon 2) and NANOG1/2-speciﬁc
oligonucleotides 50-CACCTATGCCTGTGATTTGTGG-
30 and 50-TTGTTTGCCTTTGGGACTGG-30 (hy
dridizing to NANOG1/2 exons 3 and 4).
50-RACE experiments
All 50-RACE experiments were performed by using the
Invitrogen RACE Kit according to the manufacturer’s in-
structions. Brieﬂy, 5mg of extracted RNA was used for the
initial dephosphorylation step and a subsequent
decapping step resulting in a 50-phosphate only at bona
ﬁde mRNA molecules. Next, a ligation with an 44-nt
long RNA oligonucleotide was performed, leading to
50-tagged RNA molecules. Then, a ﬁrst strand cDNA syn-
thesis was performed using a NANOG-speciﬁc oligo-
nucleotide (50-GTTGCTCCACATTGGAAGG-30) that
speciﬁcally binds to the ﬁnal exon. After completion of
ﬁrst strand cDNA synthesis, two consecutive PCR reac-
tions were performed to amplify speciﬁcally NANOG1 and
NANOG2 transcripts. For the ﬁrst PCR the speciﬁc oligo-
nucleotides were used (50-CGACTGGAGCACGAGGAC
ACTGA-30;5 0-CACCAGGCATCCCTGCGTCAG-3) in
combination with a touch-down PCR protocol: 10 cycles
with 30s at 94 C and annealing and elongation for 3min
at 68–64.4 C (–0.4 C per cycle); this was followed by 25
cycles with 30s at 94 C, 30s at 64 C and 3min at 68 C.
An aliquot of the resulting ampliﬁcation products were
used for a nested PCR reaction using the oligonucleotides
50-GGACACTGACATGGACTGAAGGAGTA-30 and
50-GCCACCTCTTAGATTTCATTCTCTGGTTCTG
G-30 in combination with a second PCR program
(35 cycles with 30s at 94 C, 30s at 64 C and 90s at
68 C). Reactions were loaded on a 2% agarose gel and
the diﬀerent PCR amplimers were cut out, eluted from the
gel and cloned into the pCR4-TOPO vector (TOPO TA
Cloning Kit For Sequencing, Invitrogen, UK).
Subsequent sequence analyses using an universal T7
oligonucleotide (50-TAATACGACTCACTATAGGG-30)
revealed diﬀerent mRNA species deriving from the
NANOG1 and NANOG2 genes, respectively.
Establishment of NANOG1- and NANOG2-speciﬁc
PCR reactions
NANOG1-speciﬁc oligonucleotides were 50-CACCCACA
CGAGATGG-30 (speciﬁc for novel exon 2) and 50-CAGA
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produce PCR amplimers of 274 bp. Ampliﬁcation condi-
tions for NANOG1 were 45 cycles with 30s at 94 C, 30s at
56 C and 30s at 72 C. Oligonucleotides speciﬁcally
binding to NANOG1 and NANOG2 were 50-CCTTCAG
CAAAGAACAAAGCTTC-30 (speciﬁc for novel exon 1b)
and 50-CATCTCAGCAGAAGACATTTGCAAGG-30
(speciﬁc for novel exon 3) and produce PCR amplimers
of 195 bp (NANOG2) and 356 bp (NANOG1). In case of
exon 1b* usage, a 314-bp amplimer of NANOG2 was
obtained. Ampliﬁcation conditions for NANOG1/2-
speciﬁc transcripts were 26 cycles with 30s at 94 C, 30s
at 65–54 C (–0.5 C per cycle) and 90s at 72 C; this was
followed by 14 cycles with 30s at 94 C, 30s at 54 C and
90s at 72 C. A ﬁnal extension step at 72 C for 2min was
performed. These conditions were also used to analyze a
large variety of tissue cDNAs, biopsy material isolated
from acute leukemia patients and several control
samples. The identity of PCR-ampliﬁed NANOG1/
2-speciﬁc transcripts was veriﬁed by DNA sequencing
analyses.
Cloning and expression of NANOG1/2 protein variants
Identiﬁed splice variants of NANOG1 (A, Bb) and
NANOG2 (D1, D2c and E) were ampliﬁed using speciﬁc
oligonucleotides exhibiting appropriate restriction recog-
nition sites for further cloning into the pEXPR-IBA10-3
vector (IBA BioTAGnology, Germany), resulting in a
Strep-tag fusion to all 30-ends of the ampliﬁed NANOG1
and NANOG2 open reading frames. Successfully cloned
open reading frames were veriﬁed by sequence analyses.
Subsequently, plasmids (25mg per 15cm petri dishes)
coding for diﬀerent NANOG1 and NANOG2 protein
variants were lipotransfected into 293T cells and grown
for 2 days. Transfection eﬃciencies were monitored by
co-transfecting pEGFP plasmids (25mg per 15cm petri
dishes). GFP-positive cells were always in the range of
60–70% transfected cells. Cells were harvested and lysed
for at least 1h in a cell lysis buﬀer containing 150mM
NaCl, 20mM HEPES pH 7.5, 1% TritonX-100, 0.4mM
EDTA and a phosphatase/protease inhibitor mix. The
soluble fraction was added to Strep-Tactin Superﬂow
material and the Strep-tagged proteins were puriﬁed ac-
cording to the manufacturer’s instruction (IBA
BioTAGnology, Germany). An aliquot of the eluted
protein fractions (10ml) were used to separate the recom-
binant proteins on SDS page and blotted for subsequent
western blot experiments.
Western blot experiments
30 10
6 SEM and 1 10
6 NTERA cells were lysed in the
above mentioned lysis buﬀer. Soluble fractions (S), pellet
fractions (P) or Strep-tag aﬃnity puriﬁed recombinant
proteins were mixed in 2  La ¨ mmli buﬀer and separated
on a 12% SDS–PAGE. After blotting onto a PVDF
membrane, transferred proteins were incubated in
blocking solution (5% skim milk in 0.2% Triton X-100/
PBS) for 1h. The C-terminal NANOG mouse antibody
(clone 2C11, Abnova) was diluted 1:1000 in blocking
solution and incubated over night. The membrane was
washed three times with 0.2% Triton X-100/PBS and de-
veloped by using the ECL
TM Western Blotting Analysis
System (GE Healthcare).
Immunohistological experiments
HeLa cells were lipotransfected with pEXPr-IBA10-3
vectors (10mg for 10cm petri dishes) containing open
reading frames for diﬀerent NANOG1 and NANOG2
protein variants. After 24h cells were spread out on
cover glass and incubated for additional 24h. The cells
were ﬁxed with 100% Methanol (–20 C) for 20min at
 20 C. Cells were incubated with blocking solution
[10% goat serum, 0.1% Triton X-100 in PBS (PBST)]
for 30min. Methanol was removed by drying the cells
and subsequently rehydrating them with PBS. The
C-terminal NANOG rabbit antibody (H-155, Santa
Cruz, USA) was diluted 1:300 in blocking solution con-
taining 1% goat serum and incubated over night. Cells
were washed three times for 5min with 0.1% PBST and
incubated with FITC-conjugated anti-rabbit antibody
(111-095-003, Dianova, USA) which was diluted 1:150 in
blocking solution containing 1% goat serum. Cells were
washed three times with 0.1% PBST and treated for 1min
with 0.1mg/ml DAPI solution. After a second washing
step, cells were embedded in 0.1% DABCO/Mowiol
solution. All pictures were taken with the Axio Observer
Z1 (ZEISS), the Digital CCD Camera C4742-80-12AG
(Hamamatsu ORCA-ER) and the Volocity software
package.
Microarray analysis
Gene expression analysis was performed using the
Aﬀymetrix HG-U133 Plus 2.0 oligonucleotide micro-
arrays. Twomg of puriﬁed RNA from transfected cell
lines expressing either GFP (mock-control) or the
variants NANOG1, NANOG2D2 and NANOG2E were
converted by reverse transcription into double-stranded
cDNA (Roche Applied Science) and then puriﬁed using
the GeneChip Sample Cleanup module (Aﬀymetrix).
Then, labeled cRNA was generated using the
Microarray RNA target synthesis kit (Roche Applied
Science) and an in vitro transcription labeling nucleotide
mixture (Aﬀymetrix). The cRNA was then puriﬁed using
the GeneChip Sample Cleanup module (Aﬀymetrix) and
quantiﬁed using the NanoDrop spectrophotometer.
Eleven micrograms of labeled cRNA were fragmented.
Hybridization, washing, staining and scanning protocols
were performed on Aﬀymetrix GeneChip instruments
(Hybridization Oven 640, Fluidics Station 450Dx,
Scanner GCS3000Dx, respectively), following the manu-
facturer’s instructions. The obtained data were stringently
screened by comparing against mock-control, by their
P-values, log2-fold changes and signal intensities to
obtain only very robust data sets. Presented genes were
at least 4-fold deregulated.
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Transcriptional properties of NANOG gene family
members in MLL-rearranged and control cell lines
Transcripts of the NANOG gene/pseudogene family were
monitored by RT–PCR experiments using diﬀerent primer
combinations. As shown in Figure 1A, three diﬀerent
primer sets (a–c) were used to analyze cDNAs obtained
from four diﬀerent MLL-rearranged cell lines (t(4;11) cell
lines: SEM, RS4;11; the t(9;11) cell line NOMO1; the
t(11;19) cell line KOPN8. The NTERA-2 (human embry-
onic carcinoma) cell line served as positive control. By
using the exon-speciﬁc primer sets a and b, PCR
amplimers were obtained for all investigated cell lines
(Figure 1B, panels a and b). The forward primer of set c
binds to exclusively the 50-UTR of the NANOG1 gene,
demonstrating that NANOG1 transcripts were not
present in the investigated MLL-rearranged cell lines
(Figure 1B, panel c). Thus, we concluded that (i)
NANOG1 transcripts can be distinguished from all other
family members, and (ii) that all investigated cell lines are
only able to transcribe RNA species deriving from
NANOG2 or other NANOG pseudogenes.
Subsequent sequence analysis of 60 individual clones
that derived from NANOG amplimers of the SEM
cell line revealed a ﬁrst glimpse on the spectrum of
activated NANOG genes/pseudogenes. Comparison to
available NANOG sequences (NCBI database)
demonstrated the following genes/pseudogenes to be
transcribed in this MLL-rearranged leukemia cell line:
NANOG2 (27%), NANOGP2 (2%), NANOGP4 (55%)
and NANOGP5 (16%).
Since Booth and Holland reported for the NANOG2
gene an unusual splice event involving a cryptic exon
located about 20000-bp upstream of the NANOG2 gene,
we analyzed this possibility by using speciﬁc primers (set
d) in an RT–PCR experiment. As shown in Figure 1C,
neither NTERA-2 cells nor the two analyzed t(4;11) cell
lines SEM and RS4;11 seem to use this upstream exon that
is located in intron 1 of the SLC2A14 gene (9),
transcribing in the opposite direction relative to the orien-
tation of the NANOG2 gene.
Since NANOGP8 transcripts were not identiﬁed in the
60 clones that derived from SEM cells, we wanted to rule
out that NANOGP8 is indeed not transcribed in the
investigated cell lines. Corresponding RT–PCR
Figure 1. NANOG transcription in MLL-rearranged and Teratocarcinoma cell lines. (A) Gene structures of NANOG1 and NANOG2. Primer sets
a–c were indicated for both genes. Forward primer of primer set c binds speciﬁcally to the 50-NTR of NANOG1, and thus, enable to monitor
transcripts that derive only from the NANOG1 gene. (B) RT–PCR analysis of four diﬀerent MLL-rearranged cell lines (SEM, RS4;11, NOMO1,
KOPN8). The NTERA-2 cell line represents a human embryonic carcinoma cell line and served as positive control for all experiments. M: DNA size
marker. N: water control. (C) Validation of transcripts starting in the upstream located SLC2A14 gene. M, DNA size marker. N: water control.
(D) Validation of NANOGP8 transcription. Speciﬁc oligonucleotides that bind only to the NANOGP8 open reading frame, we were not able to detect
NANOGP8 transcripts in the investigated cells lines. M: DNA size marker. N: water control. N-P8, N2, N-P5: cloned NANOGP8, NANOG2 and
NANOGP5 cDNAs served as positive controls.
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cells and both t(4;11) cell lines. Cloned NANOG2,
NANOGP8 and NANOGP5 cDNAs were used as
positive control and to demonstrate speciﬁcity of
the applied primer sequences (set e). As shown in
Figure 1D, the investigated cell lines does not seem to
transcribe NANOGP8.
Based on these initial experiments and on the fact, that
only NANOG1, NANOG2 and the pseudogene
NANOGP8 are per se able to be translated into
NANOG proteins, we concluded that NTERA-2, the
t(4;11) cell lines and t(4;11) patient cells most likely use
NANOG1 or NANOG2 protein to activate the down-
stream core NANOG network.
RACE experiments revealed an extended gene structure
for NANOG1 and NANOG2
Based on the obtained experimental results, 50-RACE
experiments were conducted with cDNA obtained from
NTERA-2 and the SEM cell line by using an anchored
oligonucleotide in the ﬁnal exon of the NANOG1/2 gene.
As shown in Figure 2A, several but diﬀerent PCR bands
were obtained for both investigated cell lines. Therefore,
all RACE–PCR amplimers were cut out from the gel and
cloned. Subsequent sequence analyses revealed the
presence of NANOG1 and NANOG2 transcripts in
NTERA-2 cells, and NANOG2 transcripts in SEM cells.
The large number of analyzed clones allowed us to identify
complex splice patterns in transcripts deriving from both
NANOG genes. In addition, the presence of novel 50-exons
for both NANOG genes revealed extended gene structures.
As shown in Figure 2B, the NANOG1 gene exhibits three
additional exons, named exon 1a, 1b/1b* and 2, while the
NANOG2 gene exhibits an additional exon 1b/1b*.
Surprisingly, exon 2 seems to be absent, however, a
careful analysis of genomic sequences revealed that there
exists an NANOG2 exon 2 remnant, missing most of its
30-portion due to an ALU integration event. Based
on these ﬁndings, we propose an revised exon/intron
structure for both NANOG genes which is depicted in
Figure 2B. The yet known gene structures for both genes
Figure 2. RACE experiments reveal splice variations of NANOG1 and NANOG2 and novel upstream exons. (A)5 0-RACE experiment. NTERA-2
and SEM cDNA was analyzed by using an anchored primer in the ﬁnal NANOG exon. I–IV: bands cut out from the gel, cloned and sequenced. M:
50-bp ladder; N: water control. (B) Extended gene structure for NANOG1 and NANOG2. Homologous regions between both genes are depicted by
grey areas. Repetitive DNA elements are indicated. Potentially transcriptional active ALU-elements are shown in light grey, while promoter-mutated
ALU-elements are shown in dark grey. MER: MER-repeat. Arrows: indicate transcription initiation sites. All exons are numbered according to the
nomenclature used throughout the manuscript. (C) Splice variants of NANOG1 and NANOG2. All cloned RACE amplimers were sequenced and
revealed the additional NANOG1 exons 1a, 1b, 1b*, 2 and NANOG2 exons 1b, 1b*. Open reading frame analyses (marked in grey) of all cloned
splice variants revealed putative open reading frames (ORFs) coding for two NANOG1 (splice variants A and B) and three NANOG2 protein (splice
variants D, E and F). The number of isolated cDNA clones is indicated. Length of ORFs, predicted molecular weight (MW) and putative protein
structures are depicted for all NANOG1/2 mRNA variants.
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an earlier report (9) already described exon 1b in tran-
scripts deriving from the NANOG1 gene.
Detailed overview about the novel NANOG1 and
NANOG2 gene structures
NANOG2 most likely represents a tandem duplication of
the NANOG1 gene located at 12p13.31. Both genes are
separated by about 80kb, a genomic region coding
for the SLC2A14 gene. Based on our results, the
NANOG1 gene exhibits two alternatively used ﬁrst
exons (1a and 1b/1b*) that both splice to the consecutive
exons 2–6. For the NANOG2 gene, we identiﬁed only tran-
scripts containing exon 1b/1b* sequences, although the
presence of a NANOG2 exon 1a could be identiﬁed in
the genomic DNA.
Both genes are highly saturated with repetitive ALU
elements. All ALU integration events are unique
for both genes, indicating that both NANOG gene
copies diverged during the evolution. Although both
NANOG genes seem to be quite diverse, the regions
upstream and surrounding NANOG1/2 exons 1a/b are
highly conserved (90 and 85% identity), similar to the
region upstream of NANOG1/2 exons 3 that display
90% identical nucleotides. All other intronic sequences
are much less conserved and show very little homology.
This indicated that the regions used as transcriptional
start sites of both NANOG genes have been conserved
during evolution.
Alternative splice variants of NANOG1 and NANOG2
A series of diﬀerent splice variants for NANOG1- (n=7;
named A and Ba–c) and NANOG2-derived transcripts
(n=7; named D1, D2a-c, D2*, E and F) were cloned
(Figure 2C). All these variant mRNAs can be potentially
translated into 2 diﬀerent NANOG1 (predicted MW: 32
and 35kDa) and three diﬀerent NANOG2 proteins
(predicted MW: 19, 27 and 29kDa). Splice variant A is
derived from transcripts starting upstream of NANOG1
exon 3 and uses the ﬁrst AUG start codon of exon 3;
this transcript encodes an open reading frame with the
potential to produce a protein with a predicted molecular
weight (MW) of 35kDa. Splice variants B come in many
diﬀerent ﬂavors, because exons 1a, 1b or 1b* are used for
splice processes to consecutive exons 2–6 of NANOG1.
Moreover, splice processes between exons 2 and 3 result
in exon 2 sequences fused to nt+3,+6 or+17 of exon 3,
thereby skipping 2, 5 or 16 nt. All these diﬀerent mRNAs
lead to shorter open reading frames with the potential to
produce a protein with a predicted MW of 32kDa. In a
few of these NANOG1 transcripts, alternative splicing is
leading to the skipping of the ﬁrst 48 nt of exon 6. This
results in the loss of 16 amino acids of the CD1 domain
which has previously been described (13).
The NANOG2 gene gives rise to splice variants D–F.
Splice variant D1 is similar to splice variant A of the
NANOG2 gene. However, due to several missense muta-
tions, the ﬁrst two AUG start codons in exon 3 are absent,
and thus, this splice variant encodes a protein with a pre-
dicted MW of 29kDa. Splice variant D2 comprises
transcripts that use either exon 1b or 1b*. Exon 1b is
spliced to exon 3 by fusing exon 1b sequences again with
nts +3, +6 or +17 of exon 3. Presumably due to the
missing exon 2 in the NANOG2 gene structure, exon 1b*
splice events fuse exon 1b* with nt +77 of exon 3; these
diﬀerent mRNAs all encode a NANOG2 protein variant
with a predicted MW of 29kDa. Splice variant E fuses
exon 1b with exon 4, resulting in an open reading frame
that can be translated into a 27kDa protein. Finally,
splice variant F is nearly identical to splice variant D2,
however, exon 3 is fused to nt +39 of exon 4. This
results in another open reading frame that potentially
encodes a protein of 19kDa. Moreover, all cloned
NANOG2 splice variants exhibit the skipping of the ﬁrst
48 nt of exon 6. The number of all cloned splice variants,
the length of the potentially encoded open reading frames,
the predicted MW and the protein domain structure of
both NANOG genes are depicted in Figure 2C. All
primary sequences and a complilation of all identiﬁed
splice sites can be retrieved from the Supplementary
Data (Supplementary Figures S1 and S2).
Western blot experiments revealed diﬀerent NANOG
protein variants
Western blot experiments with soluble cell lysates (S) of
NTERA-2 cells revealed the expression of several protein
bands. NTERA-2 cells transcribe both the NANOG1 and
NANOG2 gene in a large variety of diﬀerent splice
variants. This results in weaker and stronger visible
protein bands in the western blot experiments. Stronger
protein bands seem to have a MW of 48, 35 and 29kDa,
respectively (see Figure 3A, left panel). SEM cells, shown
to transcribe only the NANOG2 gene, expressed a strong
48kDa and a weak 29kDa protein variant (see Figure 3A,
right panel).
In order to validate that the predicted MW of the dif-
ferent splice variants of both genes and migration
behavior in SDS–PAGE are similar, we performed recom-
binant protein expression in 293T cells. Several splice
variants were cloned into the pEXPR-IBA10-3 vector
system (A, Bb, D1, D2c and E). This vector fuses a
4kDa Strep-Tag to the C-terminus of all open reading
frames. After transient transfection into 293T cells, all
NANOG variants were aﬃnity-puriﬁed and analyzed by
western blot experiments. As shown in Figure 3B, two
diﬀerent NANOG1 and NANOG2 protein variants were
successfully expressed in mammalian 293T cells. The
NANOG1Bb, NANOG2D2c and NANOG2E protein
variants migrated with their expected molecular weight
(32+4=36, 29+4=33 and 27+4=31 kDa, respective-
ly). By contrast, the NANOG1A variant migrated at  50
kDa. This indicated that the NANOG1A protein seems to
be subjected to post-translational modiﬁcations (PTM).
The recombinant NANOG1A protein was subjected to
mass spectrometry and veriﬁed to be the Strep-tagged
NANOG1 protein (Supplementary Figure S3). However,
all our attempts to uncover the potential PTM failed so
far. Therefore, we have no explanation for the observed
shift of about+11kDa (35+4=39) in SDS–PAGE.
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To further investigate the cellular distribution of diﬀerent
NANOG1/2 protein variants, we performed immunohis-
tological experiments. As shown in Figure 3C, expression
and cellular localization of the recombinant NANOG1/2
protein variants was monitored by using an antiserum
raised against the C-terminal portion of NANOG in com-
bination with DAPI staining. After transient transfection
of all constructs into HeLa cells, the NANOG1/2 protein
variants localized in the nucleus. Thus, it can be concluded
that all diﬀerent NANOG1/2 protein variants are per se
able to translocate into the nucleus, where these protein
variants are able to provide their speciﬁc function(s).
Establishment of NANOG1- and NANOG2-speciﬁc
RT–PCR conditions
Since the novel gene structures of NANOG1 and
NANOG2 exhibit additional exons that are absent in all
known NANOG pseudogenes, they provide a perfect
source to establish NANOG1- and NANOG2-speciﬁc
PCR reactions. This may help to experimentally distin-
guish between bona ﬁde NANOG gene transcripts and
non-functional transcripts deriving from all other
NANOG pseudogenes. In Figure 4 the ﬁrst exons of the
NANOG1 and NANOG2 gene are depicted. By using the
speciﬁc primers A and C, we were able to establish speciﬁc
conditions that speciﬁcally amplify only transcripts
Figure 3. Western blot experiments, recombinant expression of NANOG1 and NANOG2 variants in 293T cells and immunohistological experi-
ments. (A) Western blot experiments using an antiserum against the C-terminal portion of NANOG protein revealed the expression of NANOG1
and NANOG2 protein variants in NTERA-2 cells, and NANOG2 in SEM cells. (B) Cloned Strep-aﬃnity-tagged splice variants of NANOG1 and
NANOG2. Predicted molecular weight of all expression constructs is indicated. Recombinant expression of NANOG1 splice variants A and Bb and
NANOG2 splice variants D2c and E in 293T cells were shown. Sizes of protein markers are indicated. (C) Immunohistological analysis of all
recombinant NANOG1/2 protein variants expressed in Hela cells. Selected pictures from transfected cells were taken (20 ). From left to right: phase
contrast, anti-C NANOG antiserum, DAPI counter-staining and a merged picture is shown. All NANOG1/2 protein variants were localized within
the nucleus of transfected cells.
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gene encodes the additional exon 2, the resulting two dif-
ferent PCR amplimers indicate transcription of NANOG1
(356 bp) and NANOG2 (195 bp). In case of using the
exons 1b* splice sites, the NANOG1-speciﬁc transcript
will result in a 770-bp amplimer, while the
NANOG2-speciﬁc transcript will result in a 314-bp
amplimer. All experiments were controlled by using total
RNA isolated from NANOG1Bb- and NANOG2D2c-
transfected 293T cells (Figure 4, right upper panel). The
results of these experiments clearly revealed that
NTERA-2 cells transcribe both NANOG genes, while
SEM cells exclusively transcribe the NANOG2 gene. The
combination of primers B and C veriﬁed these results,
since this PCR detected only transcripts deriving from
the NANOG1 gene (274 bp amplimer). Thus, speciﬁc con-
ditions were established that allow to distinguish between
transcripts deriving from NANOG1 alone (B–C),
NANOG1 and NANOG2 (A–C) from all other pseudogene
transcripts of the NANOG gene family (Figure 1B, primer
Figure 4. NANOG1/2-speciﬁc RT–PCR experiments. (A) The two promoter regions of each NANOG genes are highlighted. Oligonucleotides A–C
are indicated. Right upper panel: RT–PCR experiments using the primer combination A/C which allowed to monitor NANOG1- and NANOG2-
derived transcripts. Right lower panel: RT–PCR experiments using the primer combination B/C, which allowed to monitor only NANOG1-derived
transcripts. As internal control, cDNA from transfected cells were used (NANOG1 Bb and NANOG2 D2c) and analyzed under identical conditions.
N: water control. (B) Tissue cDNA panel. By using the primer combination A/C, a tissue cDNA panel was tested. With the exception of CD34
+
cells, all other investigated tissue cDNAs remained negative. M: DNA size marker; neg: water control. Middle panel: Screening of t(4;11) patients,
healthy volunteers and positive controls. Seven out of ten analyzed t(4;11) patients transcribed the NANOG2 gene. Peripheral blood samples of
healthy volunteers were negative. M: DNA size marker; neg: water control. Lower panel: Screening of AML patients with normal karyotype. Out of
20 samples, 16 were positive for NANOG2 transcription, while 5 out of 20 samples were also positive for NANOG1 transcripts. Only 17 out of 20
analyses are shown. M: DNA size marker.
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MLL-rearranged cell lines are able to transcribe the
NANOG2 gene.
By using the primer combination A–C, we investigated
a tissue cDNA panel for NANOG transcripts. As shown in
Figure 4B (upper panel), only CD34
+cells seem to express
a 314-bp amplimer. This derives from the NANOG2 gene
by using the exon 1b* splice site (Figure 4A). Thus CD34
+
cells transcribe the NANOG2 but not the NANOG1 gene.
All other tissues remained negative, as well as the
investigated healthy individuals (n=3). The same experi-
ment was performed with leukemia biopsy material of
t(4;11) patients and AML patients with normal karyotype
(Figure 4B, middle and lower panels). These experiments
revealed that leukemia patients weakly express predomin-
antly NANOG2 (1b=195 and 1b*=314 bp), while some
AML samples were also weakly transcribing NANOG1
(1b=356 bp). Several bands were cut out from the gel
and subjected to DNA sequencing analysis. In all cases,
the appropriate NANOG1 or NANOG2 transcript could
be conﬁrmed. The weak amplimer production can be
explained by two possibilities: (i) all cells produce only
very few transcripts, or, (ii) only a minor fraction of
the analyzed leukemia cells transcribe the NANOG
genes. Based on immunohistochemistry experiments
(Supplementary Figure S4), we assume that only a
minor fraction of cells is expressing the NANOG or
OCT4 protein. We also conducted QPCR experiments to
analyze the absolute amount of transcripts produced by
the two alternative start sites in the NANOG1 gene.
For this purpose, PCR experiments were performed with
total RNA isolated from NETRA-2 cells. The amount of
transcripts between exon 1b/2 and exon 3/4 were
measured. For quantiﬁcation, we used a log-diluted
NANOG1Bb expression plasmid (1–10
6 copies;
Supplementary Figure S5). This allowed us to calculate
the initiation events of transcripts starting upstream of
exon 1b (10000 transcripts in cDNA derived from
100ng total RNA; assuming 15fg total RNA per
cells=1 transcript in 600 cells) and exon 3 (490000 tran-
scripts in cDNA deriving from 100ng total RNA;
assuming 15 fg total RNA per cell=1 transcript in 12
cells). Thus, the transcriptional start site upstream of
NANOG1 exon 3 is about 50-fold more used than the
start site upstream of exon 1b, assuming that both
NANOG genes are equally transcribed. QPCR experi-
ments could not be performed for the NANOG2 gene,
because of the multitude of diﬀerent-sized PCR bands in
splice variants D2, D2*, E and F did not allow reliable
quantiﬁcation.
Gene expression studies
To understand the biological signiﬁcance of the diﬀerent
NANOG1/2 protein variants, we used an episomal vector
system (pEPI) to express three diﬀerent NANOG protein
variants (1A, 2D2 and 2E) in 293 cells. The pEPI-EGFP
vector encodes an additional EGFP reporter gene and the
neomycin resistance gene. An empty pEPI-EGFP vector
expressing only the EGFP protein served as negative
control and was kept under identical conditions. After
69 days of cell culture, about 60% of the diﬀerent cell
populations were green ﬂuorescent and total RNA was
prepared. These RNA samples were used to perform
gene expression proﬁling experiments using available
Aﬀymetrix chips (Figure 5A). Subsequent analysis
revealed a speciﬁc activation of very few genes in all
three transfected cell populations. All investigated
NANOG1/2 protein variants strongly induced FOS gene
transcription (NANOG1A: 39-fold; NANOG2D2:
30-fold; NANOG2E: 30-fold). The FOS protein is able
to bind directly to several other transcription factors or
nuclear complexes (ATF2, BCL3, COBRA1, CREBBP,
CSNK2A1, CSNK2A2, DDIT3, ETS2, GTF2E2,
GTF2F1, JUN, MITF, NACA, NCOA1, NCOA6,
NCOR2, PML, RPS6KA4, RUNX1, RELA, RUNX2,
SMAD3, SPI1, TAF1, TBP, TCF1, TSC22D3, VDR,
XBP1). The second gene that was transcriptionally
activated was the EGR1 gene (5- to 6-fold). This zinc
ﬁnger transcription factor directly interacts with several
other nuclear factors (CEBPB, CREBBP, EP300,
ERBB3, NAB1, NAB2, NFATC1, PITX1, PSMA3,
RELA, TP53). Most importantly, EGR1 is able to tran-
scriptionally upregulate the CDKN1A/p21 gene. The acti-
vation of the CDKN1A/p21 gene was recently shown to be
a key step for cancer stem cell quiescence and maintenance
(14). Thus, ectopic activation of diﬀerent NANOG
protein (variants) in non-ES cells may allow to activate
a speciﬁc genetic program (Figure 5B). Based on recent
ﬁndings, the transcriptional activation of p21 is
p53-independent and one of the key features for tumor
stem cells to aquire stem cell maintenance and drug
resistance.
DISCUSSION
NANOG is a homeodomain transcription factor that is—
in conjunction with OCT4 and SOX2—responsible to
establish a genetic circuit to maintain the stem cell com-
partment at the blastocyst stage of developing embryos
(3,4). This important concept has recently been veriﬁed
and extended by the genetic manipulation of diﬀerentiated
cells with four diﬀerent transgenes (Klf4, Oct4, Sox2 and
c-Myc). Transient expression of these proteins led to the
activation of the NANOG gene, and subsequently to a
reprogramming of the manipulated cells into induced
pluripotent stem cells (iPS) (15,16).
Many reports have demonstrated transcription of
‘NANOG’ in germ cells (17,18) and other human cancer
tissues (11,12). In most of these reports, the authors were
only able to distinguish between transcripts deriving from
NANOG1, NANOG2 (10) or NANOG pseudogenes by
cloning and sequencing the obtained PCR amplimers.
However, only NANOG1-, NANOG2- and NANOGP8-
derived transcripts are per se able to be translated into
protein, while all other pseudogenes do not exhibit
intact open reading frames (9).
This study tried to answer the question whether human
cancer cells express either NANOG1 or the functional
equivalents NANOG2 and NANOGP8, respectively.
Expression of functional NANOG proteins may help to
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a key event to establish and maintain cancer stem cells. To
answer this important question and to validate our earlier
ﬁnding, namely that t(4;11) leukemia cells transcriptional-
ly upregulate NANOG transcripts (8), we started to inves-
tigate the transcriptional properties of NANOG genes and
pseudogenes in MLL-rearranged cells lines.
First, the analysis of transcriptional properties of
NANOG1 and NANOG2 in NTERA-2 and MLL-
rearranged cell lines led to the discovery of novel
50-exons which reﬂect on more extended gene structures
for NANOG1 and NANOG2, respectively (Figure 2B).
Several splice variants of both NANOG genes were
cloned which putatively encode diﬀerent NANOG1/2
protein variants (Figure 2C). The diﬀerent NANOG
protein variants display a shorter N-terminal domain
(ND), without aﬀecting the important homeobox
domain (HD). The ND was shown to be dispensable for
the function of human NANOG protein, because the
transactivation domain is located in the C-terminal
domain CD of human NANOG protein (19). Only
the NANOG2F variant displayed a partial loss of the
HD domain. Thus, all other NANOG1/2 protein
variants seem to contain all necessary domains to exhibit
similar functions. Noteworthy, the existence of exon 1b as
part of the NANOG1 gene has been described earlier (9),
however, the authors did not further investigated their
own ﬁndings.
NTERA-2 cells transcribe several splice variants
deriving from the NANOG1 and NANOG2 gene. By
using an antiserum speciﬁc for the C-terminal portion of
NANOG protein, diﬀerent NANOG1 and NANOG2
protein variants were detected in western blot experi-
ments. By contrast, the investigated t(4;11) cell line SEM
predominantly expresses a 48kDa protein. By using
recombinant expression in HeLa cells, we could demon-
strate that all tested NANOG1/2 protein variants
translocated into the nucleus. This may indicate that all
Figure 5. Gene expression proﬁling experiment. (A) The cell line 293 was transfected with episomal pEPI-EGFP vector containing expression
cassettes for NANOG1A, NANOG2D2c or NANOG2E. After 10weeks of culture, GPF-positive cells were sorted and used for RNA isolation.
These RNA samples were used for Aﬀymetrix chip experiments, resulting in few deregulated genes shown in the right. White boxed areas:
up-regulated genes. Light grey boxed areas: down-regulated genes. Common genes identiﬁed in all three experiments using the diﬀerent
NANOG1/2 protein variants are highlighted. (B) Mode of action for the investigated NANOG protein variants. NANOG protein is able to
induce transcription of EGR1 (directly or indirectly). EGR1 protein is directly binding to the promoter regions of FOS and p21. P21 protein is
necessary for stem cell maintenance, while the FOS transcription factor is necessary for cell proliferation.
Nucleic Acids Research, 2010,Vol.38, No. 16 5393these diﬀerent NANOG protein variants are able to
function as transcription factors.
Based on the extended gene structures we established
speciﬁc PCR conditions that allow to precisely distinguish
between transcripts that derive from NANOG1 (B–C
amplimer in Figure 4), NANOG2 (A–C amplimer in
Figure 4) or all other NANOG pseudogene copies
(primer sets a and b in in Figure 1B). Thus, the analysis
of transcriptional properties in stem cells, cancer cells or
any other cell line will become more accurate and reliable
in the future. Because of the importance of this ﬁnding, we
validated independently the existence of these NANOG1/2
upstream transcripts by RNase protection experiments
(Supplementary Figure S6). These experiments validated
all prior experiments, thus demonstrating that the novel
upstream NANOG1/2 exons are existing and no cloning
artifact. Therefore, the established PCR assay could be
reliably used as read-out system for the transcriptional
activity of both stem cell genes without detecting any
other pseudogene.
To investigate this a bit deeper, we analyzed the chro-
matin properties of both NANOG genes. This revealed
open chromatin structures (H3K4me) in the promoter
regions of both NANOG genes in NTERA2 cells, while
the leukemia cell lines SEM and RS4;11 displayed open
chromatin structures predominantly in the upstream
region (region I and II) of the NANOG2 gene
(Supplementary Figure S7). The existence of these novel
upstream promoter regions was further validated
by Luciferase reporter gene assays. These experiments
demonstrated that both DNA sequences located directly
50 to exon 1b function as promoter elements after transi-
ent transfection into NTERA2 cells (Supplementary
Figure S8).
For the ﬁrst time, the NANOG2 gene was shown to be
transcribed in CD34
+cells (Figure 4B). This may indicate
that the hematopoietic stem compartment may use the
NANOG system to gain stem cell like properties. The
same is true for most investigated leukemia samples that
predominantly produced NANOG2D transcripts. We
veriﬁed this ﬁnding by performing western blot experi-
ments with biopsy material of acute myeloid leukemia
patients (n=10). We were able to validate NANOG
protein expression in 4 out of 10 investigated leukemia
patients (Supplementary Figure S9).
We further investigated the functional consequences of
expressed NANOG1/2 proteins. For this purpose we used
the NANOG1A, NANOG2D and NANNOG2E variants.
These three NANOG variants were expressed for 69 days
and remaining green ﬂuorescent cells were used for RNA
extraction. After substracting against GFP-expressing
mock-transfected cells that were maintained in parallel,
the speciﬁc expression proﬁles were obtained.
Surprisingly, only very few genes were transcriptionally
deregulated. Since we expressed the NANOG variants in
293 cells, we did not see an overlap with the known
core NANOG network (3,4). However, the genes FOS
and EGR1 were transcriptionally activated. EGR1
directly binds to the promoter region of the FOS and
CDKN1A/p21 gene (20), and serves as gatekeeper for
p53 expression (21). Beside the diﬀerent functions in ES
cells, ectopic NANOG protein expression may exhibit
additional and yet unknown functions in non-ES cells
that need to be investigated further.
In conclusion, we have identiﬁed additional exons re-
ﬂecting on an extended gene structure of NANOG1 and
NANOG2. Moreover, we have revealed complex splice
patterns for both NANOG genes that are putatively
translated in a large variety of diﬀerent NANOG1/2
protein variants. We have also demonstrated that the
NANOG2 gene is transcribed in CD34
+ and diﬀerent
leukemia cells. Western blot experiments performed with
t(4;11) cell lines demonstrated that the NANOG2 protein
is produced, potentially helping to maintain stem cell
functions. We also demonstrated functional equivalence
for NANOG1 and NANOG2 protein variants in terms
of their downstream target genes. Further studies are
ongoing, aiming to understand the molecular conse-
quences of NANOG2 expression in leukemic cells with
MLL rearrangements.
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